|
Match
|
Document |
Document Title |
|
|
7618649 |
Extended release oral dosage composition
A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and...
|
|
|
7611728 |
Osmotic delivery of therapeutic compounds by solubility enhancement
The present invention is directed to the oral osmotic delivery of therapeutic compounds that have limited solubility in an aqueous environment due to inherent hydrophobicity or to saturation...
|
|
|
7601347 |
Methods and compositions for controlled release of bioactive compounds
A controlled release pharmaceutical dosage form for bacteriophage is presented. The dosage form is prepared by drying the active ingredient together with a dispersion or solution of...
|
|
|
7595063 |
Compressed tablet formulation
This invention relates to a 50% drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the...
|
|
|
7585520 |
Compositions containing both sedative and non-sedative antihistamines and sleep aids
Compositions containing both a sedative compound and a non-sedative antihistamine are provided. More particularly, compositions for administration at bedtime containing a sedating antihistamine or...
|
|
|
7575760 |
Chewable tablet containing lysine
A tablet with enhanced compliance by humans, in particular children and/or juveniles, comprising:
(a) a vitamin; (b) lysine or a pharmaceutically acceptable salt thereof; (c) a sweetener;...
|
|
|
7572463 |
Oral dosage forms
A controlled-release oral dosage formulation of a salt-forming active ingredient, wherein the active ingredient is present as at least two different salts in a solid aggregation state, wherein the...
|
|
|
7566462 |
Stable tablet formulation
The present invention is directed to a stable solid formulations of tetrahydrobiopterin, processes for producing them, and treatment methods using such formulations.
|
|
|
7538094 |
Composition containing ribavirin and use thereof
Ribavirin formulations are disclosed for use in capsules or tablets as well as processes for their preparation and methods for their administration.
|
|
|
7537784 |
Modified release tablet of bupropion hydrochloride
A modified-release tablet of bupropion hydrochloride comprising (i) a core comprising an effective amount of bupropion hydrochloride, a binder, a lubricant; and (ii) a control releasing coat...
|
|
|
7527808 |
Amorphous cefditoren pivoxil composition and process for producing the same
An objective of the present invention is to provide an amorphous cefditoren pivoxil composition possessing excellent stability and dissolvability and to provide a production process of the...
|
|
|
7517402 |
Composition comprising a phosphate binder and its preparation
A binder, a composition, a product and a kit, as well as a process for preparing the binder and composition, are directed to a composition useful as an inorganic phosphate binder, which binder is...
|
|
|
7510728 |
Solid preparations
In a solid pharmaceutical preparation containing 1) a basic medicinal component having an unpleasant taste; 2) a saccharide; 3) a polyanionic polymer; 4) a corrigent; and 5) carboxymethylcellulose,...
|
|
|
7494668 |
Fast water-dispersible domperidone tablets
The present invention relates to fast water-dispersible tablets containing domperidone for oral administration. The formulations comprise domperidone or pharmaceutically acceptable salts thereof,...
|
|
|
7488498 |
Antidiabetic preparation for oral administration
There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a...
|
|
|
7485319 |
Doxycycline metal complex in a solid dosage form
The present invention is a solid dosage form of a doxycycline metal complex. The present invention also includes a process for making a doxycycline metal complex in a solid dosage form. The process...
|
|
|
7482022 |
Palatable chewable tablet
A palatable chewable tablet is described herein for oral administration of cetirizine dihydrochloride. The formulation is made more palatable by incorporating a combination of a grape flavoring...
|
|
|
7470435 |
Extended release venlafaxine formulation
A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.
|
|
|
7445796 |
Pharmaceutically active particles of a monomodal particle size distribution and method
A method of obtaining improved reproducibility of dissolution profiles of dosage forms containing pharmaceutically active particles includes steps of screening raw pharmaceutically active particles...
|
|
|
7431943 |
Controlled release and taste masking oral pharmaceutical compositions
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic,...
|
|
|
7431942 |
Orally disintegrable tablets
An orally disintegrable tablet of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated...
|
|
|
7427413 |
Stable shaped particles of crystalline organic compounds
The present invention provides storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred...
|
|
|
7417022 |
Compounds and compositions for delivering active agents
Modified amino acid compounds useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
|
|
7416738 |
Modified release dosage form
A modified release dosage form comprising at least one active ingredient and at least two cores surrounded by a shell is provided. The shell comprises at least one opening and provides for modified...
|
|
|
7402321 |
Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is...
|
|
|
7399485 |
Rapidly Disintegrable solid preparation
A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to...
|
|
|
7396542 |
Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
Provided are formulations of a stable commercial paroxetine tablet comprising paroxetine hydrochloride anhydrous, povidone, copovidone or HPMC as a binder, and an HCl free/non-hygroscopic filler,...
|
|
|
7390503 |
Ondansetron orally disintegrating tablets
An ondansetron solid orally disintegrating dosage form for oral administration having at least one first water-dispersible component or water-insoluble cellulose derivative, a component having a...
|
|
|
7357945 |
Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
Provided are formulations of a stable paroxetine hydrochloride tablet comprising paroxetine hydrochloride, povidone or copovidone as a binder, and an HCl free/non-hygroscopic filler, prepared by...
|
|
|
7351429 |
Oral solid preparation
The invention is to provide an oral solid pharmaceutical that is uniform in the content of KRP-197, having bladder-selective anticholinergic activity, being a therapeutic drug for pollakiuria and...
|
|
|
7341742 |
Simethicone containing tablet composition and method
A process and pharmaceutical composition containing simethicone and magnesium carbonate allows a higher production rate of simethicone containing tablets and a more consistent end product tablet....
|
|
|
7338667 |
Pharmaceutical formulation
The present invention concerns an extended release formulation having an accelerating erosion and/or dissolution rate of the surface of the formulation. The formulation comprises a drug having low...
|
|
|
7335380 |
Amlodipine free base
Amlodipine free base can be formulated into a convenient oral dosage form, especially a tablet, without excessive stickiness or tablet punch residue. The amlodipine free base can be crystalline...
|
|
|
7332182 |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
Disclosed in certain embodiments is an oral dosage form comprising:
a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and an irritant in an effective amount to...
|
|
|
7329418 |
Pharmaceutical tablets having height greater than width
An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically...
|
|
|
7323192 |
Immediate release tablet
An immediate release tablet is provided. The tablet comprises at least 60 weight % of an active ingredient and powdered wax having a melting point greater than about 90° C. The tablet may...
|
|
|
7318936 |
Minimization of drug oxidation in drug irradiated excipients formulations
This invention relates to compositions and methods for preventing oxidation of beneficial agents.
|
|
|
7318935 |
Pharmaceutical tablets with active and inactive segments
An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically...
|
|
|
7316819 |
Oral peptide pharmaceutical dosage form and method of production
A pharmaceutical composition for oral delivery of a peptide is in the form of a lamination having at least two layers. The first layer of the lamination includes at least one pharmaceutically...
|
|
|
7273624 |
Stable dosage forms containing ubiquinones
The invention relates to stable solid dosage forms for peroral administration containing, in addition to an ubiquinone, at least one thermoplastically processible matrix-forming auxiliary agent.
|
|
|
7273623 |
Process for preparing tannate tablet, capsule or other solid dosage forms
An active pharmaceutical ingredient is combined with tannic acid to form a tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or...
|
|
|
7255878 |
Stable benzimidazole formulation
A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric...
|
|
|
7255876 |
Composition comprises sustained-release fine particles and manufacturing method thereof
The present invention relates to a composition comprising sustained-release fine particles, characterized in that it contains sustained-release fine particles that can be used in...
|
|
|
7250176 |
Method of treating a bacterial infection
Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
|
|
|
7229643 |
Oral 2-methyl-thieno-benzodiazepine formulation
The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation.
|
|
|
7229642 |
Amino acid modulated extended release dosage form
Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an...
|
|
|
7229641 |
Rapid-melt compositions methods of making same and methods of using same
A novel rapid-melt composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal. The rapid-melt...
|
|
|
7229640 |
Paroxetine controlled release compositions
A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.
|
|
|
7214387 |
Sustained release formulations of metformin
The invention provides sustained release formulations of metformin or a pharmaceutically acceptable salt thereof, and methods of treating diabetes by administering to a patient a therapeutically...
|
|
|
7214385 |
Pharmaceutical formulation containing dye
Methods and compositions for preventing abuse of dosage forms comprising an opioid analgesic and an aversive agent (e.g., a dye) in an effective amount to deter an abuser from administering a...
|